{"id":952585,"date":"2026-04-17T15:11:25","date_gmt":"2026-04-17T19:11:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/"},"modified":"2026-04-17T15:11:25","modified_gmt":"2026-04-17T19:11:25","slug":"new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/","title":{"rendered":"New data demonstrates the unique scalability of Evaxion\u2019s AI-Immunology\u2122 platform in glioblastoma"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">\n          <b>Data analysis conducted in collaboration with a leading academic medical center shows that AI<\/b><br \/>\n          <b>\u2011<\/b><br \/>\n          <b>Immunology\u2122 enables vaccine design also for the deadly brain cancer, glioblastoma<\/b>\n        <\/li>\n<li style=\"text-align:justify\">\n          <b>Uniquely, the platform can identify a novel source of targets to include in glioblastoma cancer vaccines, potentially enhancing their efficacy<\/b>\n        <\/li>\n<li style=\"text-align:justify\">\n          <b>Data will be presented at the American Association for Cancer Research (AACR) Annual Meeting<\/b><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">COPENHAGEN, Denmark, April 17, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology\u2122 platform, announces new data demonstrating the platform\u2019s ability to also potentially develop vaccines for glioblastoma (brain cancer).<\/p>\n<p align=\"justify\">The data, which will be presented at the AACR Annual Meeting in San Diego, California, on April 22, 2026, is another confirmation of how AI-Immunology\u2122 can be applied across a range of different cancers as well as other diseases.<\/p>\n<p align=\"justify\">Evaxion has collaborated with researchers at Duke University School of Medicine to identify endogenous retrovirus (ERV)-derived antigens in tumor samples from multiple glioblastoma patients to include in vaccines to treat the deadly brain cancer, for which limited therapeutic options exist.<\/p>\n<p align=\"justify\">ERVs are tumor antigens from the dark genome. These antigens are present in tumors but absent in normal tissue, making them highly attractive targets for cancer vaccines. AI-Immunology\u2122 has unique capabilities in identifying ERVs and this opens a whole new source of antigens, which can potentially greatly improve the efficacy of cancer vaccines for glioblastoma patients, who generally have few neoantigens to target due to low mutational burden.<\/p>\n<p align=\"justify\">In addition to the ERV-derived antigens, we also identified neoantigens of sufficient quality to include in a vaccine in the majority of patients<\/p>\n<p align=\"justify\">\u201cWe are excited by these new findings confirming that AI-Immunology\u2122 is a unique platform for designing vaccines for many different cancer types, combining neoantigens with other types of antigens. This holds great potential for improving vaccine efficacy, and we are looking forward to discussing the data with both scientific stakeholders and potential business partners at the AACR Annual Meeting,\u201d says Birgitte R\u00f8n\u00f8, CSO of Evaxion.<\/p>\n<p align=\"justify\">\n        <b>Strong Proof-of-Concept<\/b><br \/>\n        <br \/>The new findings include bioinformatic analysis profiling ERV expression in patient tumor samples and vaccine design feasibility assessment as well as experimental data demonstrating immunologic responses of the discovered ERV antigens. They show that ERVs constitute a relevant antigen source that may overcome limitations imposed by low mutational burden, providing a strong Proof-of-Concept for personalized vaccines incorporating ERV-derived antigens.<\/p>\n<p align=\"justify\">\u201cThere is a dire need for better treatment options for glioblastoma, which is refractory to immunotherapy due to low mutational burden and paucity of canonical neoantigens. We are encouraged to have found a new tumor-specific antigen source in ERVs that can be targeted by vaccines alongside mutation-derived epitopes,\u201d says Professor Mustafa Khasraw, MD, who studies tumor immunobiology at Duke University School of Medicine.<\/p>\n<p align=\"justify\">\n        <b>AACR presentation details<\/b><br \/>\n        <br \/>Abstract title: Endogenous retrovirus-derived neoantigens enable a personalized cancer vaccine strategy for glioblastoma<br \/>Poster#: 6975<br \/>Session category: Immunology<br \/>Session title: Novel Models of Immunotherapy Response<br \/>Location: Poster section 8<br \/>Date\/Time: April 22, 2026, at 9am-12pm CST\/16-19 CET\u00a0<br \/>Presenter: Megan Benz, Duke University Medical Center<\/p>\n<p align=\"justify\">\n        <b>Contact information<\/b>\u00a0<br \/>Evaxion A\/S<br \/>Mads Kronborg<br \/>Vice President, Investor Relations &amp; Communication<br \/>+45 53 54 82 96 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2hWdsobIgawUWL86aazv1iiXbhrm0Vq64jz9cPDAl_wx6lsgp6zSTmkZPPAHn0GGXbWONAsk1ak86KfDaoEhoszst1gY5ZLoKgIQK3DNPW0=\" rel=\"nofollow\" target=\"_blank\">mak@evaxion.ai<\/a><\/p>\n<p align=\"justify\">\n        <b>About Evaxion<\/b><br \/>\n        <br \/>Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology\u2122. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.<\/p>\n<p align=\"justify\">With AI-Immunology\u2122 we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development<\/p>\n<p align=\"justify\">We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients\u2019 lives by providing innovative and targeted treatment options.<\/p>\n<p align=\"justify\">For more information about Evaxion, AI-Immunology\u2122 and our pipeline, please visit our <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9PcAO4hkb0xvMnDCq5Lp5KhnnrxVn0xSdxHPb-jXXUQ7cznN1k7oC6_uvYfiwBeiiAo2ahf8NCuqIOAbtiRmQA==\" rel=\"nofollow\" target=\"_blank\">website<\/a>.\u00a0<\/p>\n<p align=\"justify\">\n        <b>Forward-looking statement<\/b>\u00a0<br \/>This\u00a0announcement contains forward-looking statements\u00a0within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.\u00a0The words\u00a0\u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201chope,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201canticipate,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d and other words and terms of similar meaning\u00a0identify forward-looking statements.\u00a0Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares,\u00a0the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our\u00a0business from other significant geopolitical and macro-economic events;\u00a0and other uncertainties affecting our business operations and financial condition.\u00a0For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F\u00a0and other filings\u00a0with the US Securities and Exchange Commission (SEC), which are available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oSGUPNnXqyIcwiWqGFumJTt3a25FEUq-j9U3wtUrsqB-pKzIwpsRtyQofbgSG4kxjhU5cnnMiiDAc3jfaGjJuU7qjBbKua5n6Eu9SbTIEiDyK4Jot4FmE1mOsdQeRz05r7B6ZV9L0RSUxBwzt_zlIz_pk6DpANomZ0lzzF3Halt95A8fWFIks4T4QWuHUdKXDT6QdMr-b-4JVLg7cz-CAmERamYYql2i58Xf_RHfvSs=\" rel=\"nofollow\" target=\"_blank\"><b>www.sec.gov<\/b><\/a>.\u00a0We do not assume any obligation to update any forward-looking statements except as required by law.\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3NjQzMCM0MDIzNzY1MzQjMjI1MjA4Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/YjJhZGQxMzAtNjU4MC00ZmM0LWExOGItMDFhNzkyMjdkYTI2LTEyNjM2NDAtMjAyNi0wNC0xNy1lbg==\/tiny\/Evaxion.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Data analysis conducted in collaboration with a leading academic medical center shows that AI \u2011 Immunology\u2122 enables vaccine design also for the deadly brain cancer, glioblastoma Uniquely, the platform can identify a novel source of targets to include in glioblastoma cancer vaccines, potentially enhancing their efficacy Data will be presented at the American Association for Cancer Research (AACR) Annual Meeting COPENHAGEN, Denmark, April 17, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology\u2122 platform, announces new data demonstrating the platform\u2019s ability to also potentially develop vaccines for glioblastoma (brain cancer). The data, which will be presented at the AACR Annual Meeting in San Diego, California, on April 22, 2026, is another &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;New data demonstrates the unique scalability of Evaxion\u2019s AI-Immunology\u2122 platform in glioblastoma&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-952585","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New data demonstrates the unique scalability of Evaxion\u2019s AI-Immunology\u2122 platform in glioblastoma - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New data demonstrates the unique scalability of Evaxion\u2019s AI-Immunology\u2122 platform in glioblastoma - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Data analysis conducted in collaboration with a leading academic medical center shows that AI \u2011 Immunology\u2122 enables vaccine design also for the deadly brain cancer, glioblastoma Uniquely, the platform can identify a novel source of targets to include in glioblastoma cancer vaccines, potentially enhancing their efficacy Data will be presented at the American Association for Cancer Research (AACR) Annual Meeting COPENHAGEN, Denmark, April 17, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology\u2122 platform, announces new data demonstrating the platform\u2019s ability to also potentially develop vaccines for glioblastoma (brain cancer). The data, which will be presented at the AACR Annual Meeting in San Diego, California, on April 22, 2026, is another &hellip; Continue reading &quot;New data demonstrates the unique scalability of Evaxion\u2019s AI-Immunology\u2122 platform in glioblastoma&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-17T19:11:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3NjQzMCM0MDIzNzY1MzQjMjI1MjA4Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"New data demonstrates the unique scalability of Evaxion\u2019s AI-Immunology\u2122 platform in glioblastoma\",\"datePublished\":\"2026-04-17T19:11:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\\\/\"},\"wordCount\":929,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3NjQzMCM0MDIzNzY1MzQjMjI1MjA4Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\\\/\",\"name\":\"New data demonstrates the unique scalability of Evaxion\u2019s AI-Immunology\u2122 platform in glioblastoma - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3NjQzMCM0MDIzNzY1MzQjMjI1MjA4Nw==\",\"datePublished\":\"2026-04-17T19:11:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3NjQzMCM0MDIzNzY1MzQjMjI1MjA4Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3NjQzMCM0MDIzNzY1MzQjMjI1MjA4Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New data demonstrates the unique scalability of Evaxion\u2019s AI-Immunology\u2122 platform in glioblastoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New data demonstrates the unique scalability of Evaxion\u2019s AI-Immunology\u2122 platform in glioblastoma - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/","og_locale":"en_US","og_type":"article","og_title":"New data demonstrates the unique scalability of Evaxion\u2019s AI-Immunology\u2122 platform in glioblastoma - Market Newsdesk","og_description":"Data analysis conducted in collaboration with a leading academic medical center shows that AI \u2011 Immunology\u2122 enables vaccine design also for the deadly brain cancer, glioblastoma Uniquely, the platform can identify a novel source of targets to include in glioblastoma cancer vaccines, potentially enhancing their efficacy Data will be presented at the American Association for Cancer Research (AACR) Annual Meeting COPENHAGEN, Denmark, April 17, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology\u2122 platform, announces new data demonstrating the platform\u2019s ability to also potentially develop vaccines for glioblastoma (brain cancer). The data, which will be presented at the AACR Annual Meeting in San Diego, California, on April 22, 2026, is another &hellip; Continue reading \"New data demonstrates the unique scalability of Evaxion\u2019s AI-Immunology\u2122 platform in glioblastoma\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-17T19:11:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3NjQzMCM0MDIzNzY1MzQjMjI1MjA4Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"New data demonstrates the unique scalability of Evaxion\u2019s AI-Immunology\u2122 platform in glioblastoma","datePublished":"2026-04-17T19:11:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/"},"wordCount":929,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3NjQzMCM0MDIzNzY1MzQjMjI1MjA4Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/","name":"New data demonstrates the unique scalability of Evaxion\u2019s AI-Immunology\u2122 platform in glioblastoma - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3NjQzMCM0MDIzNzY1MzQjMjI1MjA4Nw==","datePublished":"2026-04-17T19:11:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3NjQzMCM0MDIzNzY1MzQjMjI1MjA4Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3NjQzMCM0MDIzNzY1MzQjMjI1MjA4Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"New data demonstrates the unique scalability of Evaxion\u2019s AI-Immunology\u2122 platform in glioblastoma"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=952585"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952585\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=952585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=952585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=952585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}